Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of two oral mesalazine regimens in active ulcerative colitis
2012-001830-32Phase 3Completed
- Sponsor
- Dr. Falk Pharma GmbH
- Start
- Aug 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of Salcrozine in autoimmune colitis (2 arms), sponsored by Dr. Falk Pharma GmbH. Primary endpoint: Clinical remission rate at 8 weeks. Started Aug 2012; status: completed.
02
Drugs
Salcrozine
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on 2012-001830-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-001830-32.